For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Diovan Generics Developed as AGs, “No Comment” on December Listing: Sandoz
August 20, 2013
-
ACADEMIA Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
-
BUSINESS Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals
August 16, 2013
-
ACADEMIA British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
August 16, 2013
-
REGULATORY 3 Ex-Officials of MHLW, NHO Affiliated with Novartis in 2010, Govt Says
August 15, 2013
-
REGULATORY PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
August 14, 2013
-
REGULATORY EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
August 13, 2013
-
REGULATORY 41,254 ADR Reports Received from Marketing Authorization Holders in FY2012: MHLW
August 13, 2013
-
BUSINESS Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
August 13, 2013
-
REGULATORY MHLW Diovan Committee: 3 More Universities Give 1st Probe Updates, SMART Data Rapped “Sloppy”
August 12, 2013
-
BUSINESS AZ’s Exenatide Promotion to Break Free from Weight-Loss Image of GLP-1 Receptor Agonists
August 9, 2013
-
REGULATORY MHLW Taps 12 Experts to Serve on Diovan Study Committee; J-CLEAR’s Kuwajima, JAMS’s Sone on the List
August 9, 2013
-
REGULATORY PMDA to Make Public Adverse Reactions Reported by Patients by Year-End
August 8, 2013
-
ACADEMIA NCC Sets Sights on World’s Top Development Hub with New Exploratory Clinical Research Center
August 7, 2013
-
ORGANIZATION Kenporen Report Recommends Reference to Measures Taken in UK, France to Further Promote Use of Generics in Japan
August 7, 2013
-
ACADEMIA Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers
August 6, 2013
-
REGULATORY EAD Director to Personally Visit Hospitals to Urge Early Price Agreement
August 5, 2013
-
BUSINESS Apo Plus to Hire 1,000 Contract MRs by 2013-End
August 2, 2013
-
REGULATORY Distribution Reform and Perpetuation of Premium for New Drug Development Are Immediate Top-Priority Issues: EAD Director Jo
August 2, 2013
-
REGULATORY CSIMC Subcommittee Discusses Revisions of Drug Pricing Rules; Some Reps Oppose Proposed Rewards for Innovation
August 1, 2013
ページ
Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…